drugset / Trial / NCT00174616
CORE: Capecitabine, Oxaliplatin, Radiotherapy and Excision
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Primary objective: * Pathological complete response (ypT0N0) rate Secondary objectives: * Histopathological R0 resection rate * Pathological downstaging (ypT0-T2N0) rate * One month surgical complication rate * Predictive value of pre-operative MRI for surgical, pathological and clinical outcomes * Safety * Local and distant recurrence rates * Progression-free survival * Overall survival
Timeline
- Start
- 2003-07
- Primary completion
- 2007-11
- Completion
- 2007-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 50 mg/m2 | Intravenous |